Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit

Burns

Volumn 36, Issue 4, 2010, Pages 522-527

  Ganapathy, H ^a   Pal, S K ^a   Teare, L ^a   Dziewulski, P ^a  

^a BASILDON HOSPITAL   (United Kingdom)

Author keywords

Burns unit; Colistin; Gram negative; Multi resistant organisms

Indexed keywords

COLISTIN; CREATININE; MEROPENEM; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BURN; CHILD; CLINICAL ARTICLE; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MALE; MORTALITY; PRESCHOOL CHILD; SCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BURNS; CHILD; CHILD, PRESCHOOL; COLISTIN; CREATININE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GREAT BRITAIN; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PSEUDOMONAS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77950516253     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2009.07.010     Document Type: Article

References (47)

1. Pruitt B.A., and McManus A.T. The changing epidemiology of infection in burn patients. World J Surg 16 (1992) 57-67
2. Wurtz R., Karajovic M., Dacumos E., et al. Nosocomial infections in a burn intensive care unit. Burns 21 (1995) 181-184
3. Lee J.J., Marvin J.A., Heimbach D.M., et al. Infection control in a burn center. J Burn Care Rehabil 11 (1990) 575-580
4. Weber J.M., and Tompkins D.M. Improving survival: infection control and burns. AACN Clin Issues Crit Care Nurs 4 (1993) 414-423
5. Law E.J., Blecher K., and Still J.M. Enterococcal infections as a cause of mortality and morbidity in patients with burns. J Burn Care Rehabil 15 (1994) 236-239
6. Trouillet J.L., Chastre J., Vuagnat A., Joly-Guillou M.L., Combaux D., Dombret M.C., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157 (1998) 531-539
7. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired pneumonia study group. Intensive Care Med 22 (1996) 387-394
8. Kollef M.H., and Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113 (1998) 412-420
9. Luna C.M., Vujacich P., Niederman M.S., Vay C., Gherardi C., Matera J., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111 (1997) 676-685
10. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
11. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., and Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244 (1998) 379-386
12. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
13. Komura S., and Kurahashi K. Partial purification and properties of L-2, 4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J Biochem (Tokyo) 86 (1979) 1013-1021
14. Koyama Y., Kurosasa A., Tsuchiya A., and Takakuta K. A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot (Tokyo) 3 (1950) 457-458
15. Reed M.D., Stern R.C., O'Riordan M.A., and Blumer J.L. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41 (2001) 645-654
16. Brown J.M., Dorman D.C., and Roy L.P. Acute renal failure due to overdosage of colistin. Med J Aust 2 (1970) 923-924
17. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Finer D.C., and Eaton A.E. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72 (1970) 857-868
18. Ryan K.J., Schainuck L.I., Hickman R.O., and Striker G.E. Colistimethate toxicity: report of a fatal case in a previously healthy child. JAMA 207 (1969) 2099-2101
19. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., and Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52 (1997) 987-993
20. Cunningham S., Prasad A., Collyer L., Carr S., Lynn I.B., and Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 84 (2001) 432-433
21. Ledson M.J., Gallagher M.J., Cowperthwaite C., Convery R.P., and Walshaw M.J. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12 (1998) 592-594
22. Nakajima S. Clinical use of colimycin F otic solution [in Japanese]. Jibiinkoka 37 (1965) 693-697
23. Ohzawa R. The use of colimycin ear drops [in Japanese]. Jibiinkoka 37 (1965) 585-590
24. Michalopoulos A., Kasiakou S.K., Mastora Z., Rellos K., Kapaskelis A.M., and Falagas M.E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9 (2005) R53-R59
25. Gaynes R.P., and Horan T.C. Surveillance of nosocomial infections. Appendix A: CDC definitions of nosocomial infections. In: Mayhall C.G. (Ed). Hospital epidemiology and infection control (1996), Williams & Wilkins, Baltimore 1-14
26. Health Protection Agency. http://www.hpa-standardmethods.org.uk/pdf-sops.asp; 2004.
27. Andrews J.M. BSAC working party on susceptibility testing. J Antimicrob Chemother 48 Suppl. S1 (2001) 43-57
28. Bollero D., Cortellini M., Stella M., Carnino R., Magliacani G., and Iorio M. Pan-antibiotic resistance and nosocomial infection in burn patients: therapeutic choices and medico-legal problems in Italy. Ann Burns Fire Disast XVI December (4) (2003)
29. Gaynes R. Overview of Gram-negative nosocomial infections. Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC, October 30-November 2 (2004) [Abstract 401]
30. Davis S.D., Iannetta A., and Wedgwood R.J. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis 124 (1971) 610-612
31. Newton B.A. The properties and mode of action of the polymyxins. Bacteriol Rev 20 (1956) 14-27
32. Schindler M., and Osborn M.J. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18 (1979) 4425-4430
33. Gough M., Hancock R.E., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64 (1996) 4922-4927
34. Ledson M.J., Galagher M.J., Cowperthwaite C., Convery P.R., and Walshaw M.J. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12 (1998) 592-594
35. Colomycin package insert (2002), Forest Laboratories, UK Limited, Bexley, UK
36. Ryan K.J., Schainuck L.I., Hickman R.O., and Striker G.E. Colistimethate toxicity, report of a fatal case in a previously healthy child. JAMA 207 11 (1969) 2099-2101
37. Randall R.E., Bridi G.S., Setter J.G., and Brackett N.C. Recovery from colistimethate nephrotoxicity. Ann Intern Med 73 3 (1970) 491-492
38. Price D.J., and Graham D.I. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 4 734 (1970) 525-527
39. Goverman J., Weber J.M., Keaney T.J., and Sheridan R.L. Intravenous colistin for the treatment of multi-drug resistant, Gram-negative infection in the pediatric burn population. J Burn Care Res 28 May-June (3) (2007) 421-426
40. Falagas M.E., Kasiakou S.K., Kofteridis D.P., Roditakis G., and Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbial Infect Dis 25 9 (2006) 596-599
41. Michalopoulos A., Fotakis D., Virtzili S., Vletsas C., Raftopoulou S., Mastora Z., et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multi-drug resistant Gram-negative bacteria: a prospective study. Respir Med 102 3 (2008) 407-412
42. Levin A.S., Barone A.A., Penco J., Santos M.V., Marinho I.S., Arruda E.A.G., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 (1999) 1008-1011
43. Bosso J.A., Liptak C.A., Seilheimer D.K., and Harrison G.M. Toxicity of colistin in cystic fibrosis patients. Ann Pharmacother 25 (1991) 1168-1170
44. Conway S.P., Etherington C., Mundy J., Goldman M.H., Strong J.J., and Wooton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in patients with cystic fibrosis. Ann Pharmacother 34 (2000) 1238-1242
45. Rynn C., Wootton M., Bowker K.E., Alan H.H., and Reeves D.S. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 5 (1999) 32-36
46. Giamarellos-Bourboulis E.J., Karnesis L., and Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44 (2002) 259-263
47. Gunderson B.W., Ibrahim K.H., Hovde L.B., Fromm T.L., Reed M.D., and Rotschafer J.C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47 (2003) 905-909